Literature DB >> 8454945

Recombinant soluble IgA Fc receptor: generation, biochemical characterization, and functional analysis of the recombinant protein.

C R Maliszewski1, T VandenBos, L Shen, M A Schoenborn, H Kubagawa, M P Beckmann, R C Monteiro.   

Abstract

We previously described the cloning of a human myeloid cell surface receptor for the Fc region of immunoglobulin A (Fc alpha R). In the present study, a soluble version of the Fc alpha R (solFc alpha R) was generated by removing the transmembrane and cytoplasmic coding regions from full-length Fc alpha R cDNA and ligating into a mammalian expression vector. COS-7 cells transfected with the solFc alpha R plasmid secreted a protein that inhibited both immunoglobulin A (IgA) and anti-Fc alpha R monoclonal antibody (mAb) binding to Fc alpha R+ U937 cells. Furthermore, the solFc alpha R bound specifically to and could be eluted from an anti-Fc alpha R mAb-immunoaffinity column, retaining biological activity. Analysis by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) demonstrated that the recombinant full-length Fc alpha R migrates over a molecular mass range of approximately 40-60 kd, consistent with the reported size and heterogeneity of the naturally occurring myeloid cell surface Fc alpha R. The solFc alpha R ran on SDS-PAGE as a smaller band (37-55 kd) that reduced to two bands of 23 and 25 kd following N-glycanase treatment, indicating that the Fc alpha R is a heavily glycosylated protein. The biochemical data, coupled with flow cytometry studies showing that the recombinant Fc alpha Rs bind to five different anti-Fc alpha R mAbs, clearly demonstrate that the cloned Fc alpha R corresponds directly to the major Fc alpha R species expressed on human monocytes, neutrophils, and myeloid cell lines. The generation of soluble receptor protein will permit investigations of the role of Fc alpha R in IgA-mediated immunoregulation, effector functions, and disease.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8454945     DOI: 10.1002/jlb.53.3.223

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  7 in total

1.  Role of FcαR EC2 region in extracellular membrane localization.

Authors:  Ser-Xian Phua; Wai-Heng Lua; Samuel Ken-En Gan
Journal:  Cell Cycle       Date:  2018-04-05       Impact factor: 4.534

2.  A novel pair of immunoglobulin-like receptors expressed by B cells and myeloid cells.

Authors:  H Kubagawa; P D Burrows; M D Cooper
Journal:  Proc Natl Acad Sci U S A       Date:  1997-05-13       Impact factor: 11.205

3.  Definition of immunoglobulin A receptors on eosinophils and their enhanced expression in allergic individuals.

Authors:  R C Monteiro; R W Hostoffer; M D Cooper; J R Bonner; G L Gartland; H Kubagawa
Journal:  J Clin Invest       Date:  1993-10       Impact factor: 14.808

4.  Fc alpha receptors mediate release of tumour necrosis factor-alpha and interleukin-6 by human monocytes following receptor aggregation.

Authors:  C Patry; A Herbelin; A Lehuen; J F Bach; R C Monteiro
Journal:  Immunology       Date:  1995-09       Impact factor: 7.397

5.  Fcalpha receptor (CD89) mediates the development of immunoglobulin A (IgA) nephropathy (Berger's disease). Evidence for pathogenic soluble receptor-Iga complexes in patients and CD89 transgenic mice.

Authors:  P Launay; B Grossetête; M Arcos-Fajardo; E Gaudin; S P Torres; L Beaudoin; N Patey-Mariaud de Serre; A Lehuen; R C Monteiro
Journal:  J Exp Med       Date:  2000-06-05       Impact factor: 14.307

6.  Immunoglobulin-binding sites of human FcalphaRI (CD89) and bovine Fcgamma2R are located in their membrane-distal extracellular domains.

Authors:  H C Morton; G van Zandbergen; C van Kooten; C J Howard; J G van de Winkel; P Brandtzaeg
Journal:  J Exp Med       Date:  1999-06-07       Impact factor: 14.307

7.  Discovery of a novel splice variant of Fcar (CD89) unravels sequence segments necessary for efficient secretion: A story of bad signal peptides and good ones that nevertheless do not make it.

Authors:  Wai-Heng Lua; Wei-Li Ling; Chinh Tran-To Su; Joshua Yi Yeo; Chandra Shekhar Verma; Birgit Eisenhaber; Frank Eisenhaber; Samuel Ken-En Gan
Journal:  Cell Cycle       Date:  2017-01-19       Impact factor: 4.534

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.